drugset / Trial / NCT05471661
T Lymphocytes for the Treatment of AdV, CMV, EBV, BKV and Aspergillus Fumigatus Infections After Allogeneic Stem Cell Transplantation
Phase 1/2
Completed
10 enrolled
George Papanicolaou Hospital
University General Hospital of Patras · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of the study is to determine the feasibility, safety and efficacy of administering rapidly-generated donor-derived pentavalent-specific T cells (Penta-STs) to mediate antiviral and antifungal activity in hematopoietic stem cell transplant (HSCT) recipients with AdV, EBV, CMV, BKV or Aspergillus fumigatus (AF) infection/ reactivation or with active disease.
Timeline
- Start
- 2021-05-22
- Primary completion
- 2024-05-05
- Completion
- 2024-05-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pentavalent-specific T cells (penta-STs) | Cell therapy | — | Other |